CANCER AND LEUKEMIA GROUP B

本申请寻求对CALGB调查员活动的支持 通过北卡罗来纳大学教堂山分校参与 (北卡罗来纳大学-CH分校)和附属机构在癌症和 B组白血病。在这份修订后的申请中，我们展示了 北卡罗来纳大学及其附属机构的临床试验和推广工作的情况， 北卡罗来纳大学-中国科学院在科学和行政方面的新贡献 调查人员分组研究和委员会，以及扩大 UNC-CH应计努力，增加了两个新的附属机构， 包括位于里士满的弗吉尼亚医学院及其附属机构 退伍军人管理医院有可能积累一笔 每年增加80-100名患者进行分组研究，包括所有 疾病部位以及骨髓移植。我们的新品 UNC-CH的招募成员已经开始做出广泛的贡献 通过设计和担任主席来提高集团的智力生产力 白血病、免疫学和遗传学、化疗和治疗的新方案 生物治疗、放射治疗、呼吸和乳房委员会； 提出用于集团验证和扩展的试点观察结果； 刺激更多的基础研究组成部分开展集体活动， 特别是在生物治疗、免疫学和分子生物学方面。我们计划 通过保持活动克隆继续直接为组提供服务 以热情获得批准和资助的超额参考实验室 在最近的审查期间，并添加了生物治疗监测参考 北卡罗来纳大学-CH分校的集体生物治疗研究实验室收到了新的 在上一次拨款审查中提供资金。我们进一步扩大了集团 科学通过增加独立资助的分子研究在 与GM-CSF组方案相关的骨髓发育不良 刘爱迪生，我们癌症中心的新成员。前任成员和新成员 将扩大我们对群体科学的贡献 作为科学和技术常设小组核心成员的行政管理 管理委员会(OZER、免疫学和遗传学核心、淋巴瘤 核心、化疗核心、化疗副主任委员和生物治疗主任委员； 拉奥，细胞遗传学核心；埃文斯，精神病学核心；泰珀，放射治疗 核心和Gavigan，数据审计核心，化疗/生物治疗核心，肿瘤学 护理核心。北卡罗来纳大学-CH分校新招聘的教师将扩大我们的 乳房和手术委员会的承诺和团体参与 放射治疗(J.Tepper，J.Rosenman，S.Sailer，S. 罗利)、癌症预防(S.Fletcher)和精神病学(D.Evans)。 因此，北卡罗来纳大学及其附属机构的调查人员扩大了努力 加强CALGB在该地区的临床试验网络 弗吉尼亚州遍及北卡罗来纳州和南卡罗来纳州 增加收益并刺激肿瘤学的最新质量 该地区的关爱。对CALGB的持续参与继续发挥着以下作用 是教职员工、研究员和家政人员的重要教育工具 UNC-CH以及私人执业的外展医生 参加CALGB活动的血液科和肿瘤科医生。

This application seeks support for the activities of CALGB investigators participating through the University of North Carolina at Chapel Hill (UNC-CH) and adjunct institutions in the programs of the Cancer and Leukemia Group B. In this revised application, we demonstrate the growth of the clinical trials and outreach efforts at UNC-CH and its adjuncts, the new scientific and administrative contributions of UNC-CH investigators to Group studies and committees, and the expansion of the UNC-CH accrual effort with the addition of two new adjunct institutions, including the Medical College of Virginia in Richmond and its affiliated Veterans Administration Hospital with the potential to accrue an additional 80-100 patients annually to group studies including all disease sites as well as bone marrow transplantation. Our newly recruited members at UNC-CH have already begun to contribute extensively to the intellectual productivity of the Group by designing and chairing new protocols in Leukemia, Immunology and Genetics, Chemotherapy and Biotherapy, Radiation Therapy, Respiratory and the Breast committees; by presenting pilot observations for group validation and expansion; and by stimulating more basic research components to group activities, particularly in biotherapy, immunology and molecular biology. We plan to continue direct service to the group by maintaining an active Clonal Excess Reference Laboratory that was approved and funded with enthusiasm during the recent review and have added a Biotherapy Monitoring Reference Laboratory at UNC-CH for Group biotherapy studies that received new funding in the last grant review. We have further broadened Group science by the addition of independently funded molecular studies in myelodysplasia in association with Group GM-CSF protocols designed by Edison Liu, a new recruit to our Cancer Center. Previous and new members of our institution will expand our contribution to Group science and administration as core members of standing Group scientific and administrative committees (Ozer, Immunology and Genetics core, Lymphoma core, Chemotherapy core, Chemotherapy vice-chair and Biotherapy chair; Rao, Cytogenetics core; Evans, Psychiatry core; Tepper, Radiation Therapy Core and Gavigan, Data Audit core, Chemotherapy/Biotherapy core, Oncology Nursing core. Newly recruited faculty at UNC-CH will expand our commitment and Group participation in the Breast and Surgery committees (J.Huth,J.Mohler); Radiation Therapy (J.Tepper, J.Rosenman, S.Sailer, J.Raleigh), Cancer Prevention (S.Fletcher) and Psychiatry (D.Evans). Investigators at UNC-CH and its adjuncts have therefore expanded efforts to strengthen the CALGB clinical trials network in the region from Virginia throughout North Carolina and into South Carolina both to increase accrual and to stimulate state-of-the-art quality of oncology care in the region. Ongoing participation in CALGB continues to serve as an important educational vehicle for faculty, fellows and housestaff at UNC-CH as well as the outreach physicians in private practice of hematology and medical oncology who participate in our CALGB activities.